T
Terri S. Armstrong
Researcher at University of Texas Health Science Center at Houston
Publications - 202
Citations - 8489
Terri S. Armstrong is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 37, co-authored 148 publications receiving 6759 citations. Previous affiliations of Terri S. Armstrong include University of Tennessee Health Science Center & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert,James J. Dignam,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Deborah T. Blumenthal,Michael A. Vogelbaum,Howard Colman,Arnab Chakravarti,Stephanie L. Pugh,Minhee Won,Robert Jeraj,Paul D. Brown,Kurt A. Jaeckle,David Schiff,Volker W. Stieber,David Brachman,Maria Werner-Wasik,Ivo W. Tremont-Lukats,Erik P. Sulman,Kenneth Aldape,Walter J. Curran,Minesh P. Mehta +22 more
TL;DR: First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma, and progression-free survival was prolonged but did not reach the prespecified improvement target.
Journal ArticleDOI
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
Kristian W. Pajtler,Kristian W. Pajtler,Hendrik Witt,Martin Sill,David T.W. Jones,Volker Hovestadt,Fabian Kratochwil,Khalida Wani,Ruth G. Tatevossian,Chandanamali Punchihewa,Pascal Johann,Jüri Reimand,Hans-Jörg Warnatz,Marina Ryzhova,Steve Mack,Vijay Ramaswamy,David Capper,David Capper,Leonille Schweizer,Leonille Schweizer,Laura Sieber,Andrea Wittmann,Zhiqin Huang,Peter van Sluis,Richard Volckmann,Jan Koster,Rogier Versteeg,Daniel W. Fults,Helen Toledano,Smadar Avigad,Lindsey M. Hoffman,Andrew M. Donson,Nicholas K. Foreman,Ekkehard Hewer,Karel Zitterbart,Mark R. Gilbert,Terri S. Armstrong,Terri S. Armstrong,Nalin Gupta,Jeffrey C. Allen,Matthias A. Karajannis,David Zagzag,Martin Hasselblatt,Andreas E. Kulozik,Olaf Witt,V. Peter Collins,Katja von Hoff,Stefan Rutkowski,Torsten Pietsch,Gary D. Bader,Marie-Laure Yaspo,Andreas von Deimling,Andreas von Deimling,Peter Lichter,Michael D. Taylor,Richard J. Gilbertson,David W. Ellison,Kenneth Aldape,Andrey Korshunov,Andrey Korshunov,Marcel Kool,Stefan M. Pfister +61 more
TL;DR: The molecular classification proposed herein outperforms the current histopathological classification and thus might serve as a basis for the next World Health Organization classification of CNS tumors.
Journal ArticleDOI
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert,Meihua Wang,Kenneth Aldape,Roger Stupp,Monika E. Hegi,Kurt A. Jaeckle,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Minhee Won,Deborah T. Blumenthal,Anita Mahajan,Christopher J. Schultz,Sara Erridge,Brigitta G. Baumert,Kristen I. Hopkins,Tzahala Tzuk-Shina,Paul D. Brown,Arnab Chakravarti,Walter J. Curran,Minesh P. Mehta +20 more
TL;DR: This study did not demonstrate improved efficacy for DD temozolomide for newly diagnosed GBM, regardless of methylation status, but it did confirm the prognostic significance of MGMT methylation.
Journal ArticleDOI
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
Adriana Olar,Khalida Wani,Kristin Alfaro-Munoz,Lindsey Heathcock,Hinke F. van Thuijl,Mark R. Gilbert,Terri S. Armstrong,Terri S. Armstrong,Erik P. Sulman,Daniel P. Cahill,Elizabeth Vera-Bolanos,Ying Yuan,Jaap C. Reijneveld,Bauke Ylstra,Pieter Wesseling,Pieter Wesseling,Kenneth Aldape,Kenneth Aldape +17 more
TL;DR: Pat age, an established prognostic factor in diffuse glioma, was significantly associated with outcome only in the IDH-wild type subset, and consistent with prior data, 1p/19q co-deletion conferred improved outcome in theIDH-mutant cohort.
Journal ArticleDOI
Symptoms experience: a concept analysis.
TL;DR: Evaluation of symptoms in patients with cancer should include a meaning-centered approach, in which symptoms are evaluated not only for occurrence characteristics and perceived distress but also for the meaning of the symptoms experience to individuals.